Sheet \_1 of \_\_2

SERIAL NO. ATTY, DOCKET NO. U.S. DEPARTMENT OF COMMERCE Form PTQ 09/488,728 PATENT AND TRADEMARK 2623-B OFFICE APPLICANT ATION DISTLOSURE CITATION INFO Anthony B. Troutt FILING DATE 1646 January 20, 2000 (Use several sheets if necessary) U.S. PATENT DOCUMENTS SUBCLASS FILING DATE CLASS NAME DATE DOCUMENT NUMBER EXAMINER 02/09/99 Yao et al. 5,869,286 AA MAR 2 2 2002 TECH CENTER 1600/2900 FOREIGN PATENT DOCUMENTS TRANSLATION SUBCLASS CLASS COUNTRY DOCUMENT NUMBER DATE YES **PCT** 09/26/96 FA WO 96/29408 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Aarvak et al., "Analysis of IL-17 and other cytokines and surface markers of RA inflammatory T cell clones," American College of Rheumatology (ACR) meeting, Poster 1448. November 1997. Amin, A. R. et al., "The expression and regulation of nitric oxide synthase in human osteroarthritis-affected chondrocytes: Evidence for up-regulated neuronal nitric oxide synthase," J. Exp. Med., 182:2097-2102, December 1995. Attur, M. G. et al., "Interleukn-17 up-regulation of nitric oxide production in human osteoarthritis cartilage," Arthritis & Rheumatism, 40(6):1050-1053, 1997. Baragi, V. M. et al., "Transplantation of transduced chondrocytes-protects-articular cartilagefrom interleukin 1-induced extracellular matrix degradation," J. Clin. Invest, 96(5):2454-2460, 1995. Caron, J. P. et al., "Chondroprotective effect of intraarticular injections of interleukin-1 PE receptor antagonist in experimental osteoarthritis," Arthritis & Rheumatism, 39(9):1535-1544, 1996. Chabaud-et-al-, "Regulation-of the effects-of-IL-17-on-IL-6-and-LIF-production-by-RA-PF synoviocytes," American College of Rheumatology (ACR) meeting, Poster 1449, November 1997. DATE CONSIDERED **EXAMINER** 20na

7

\*EXAMINER: Initial if oftation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

and the second of the second o

Linkling Chin.

<del></del>		U.S. DEPARTMENT OF COMMERCE	TATTY, DOCKET NO.	SERIAL NO.	
Form P	ו-טוי	ATENT AND TRADEMARK	2623-В	09/488,728	
OFFICE		MAR 1 8 2002	2023-В	09/400,720	
INIE		SURE CITATION	APPLICANT	-	
IN ONWARD DECEMBER 1			Anthony B. Troutt	•	
			FILING DATE	1646	
		(Supplemental Sheet)	January 20, 2000	1646	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	PG Dudler et al., "In vivo effects of murine recombinant interleukin-17 on synovial joint				
		mice," American College of Rheumatolo		S 1	
	PH	Fossiez et al., "T cell interleukin-17 ind		ce proinflammatory and	
		hematopoetic cytokines," J. Exp. Med.,	<i>183</i> :2593-2603, 1996.		
	PI Fouilhoux et al., "Production of IL-17 and its regulation in rheumatoid synovium," Americ College of Rheumatology (ACR) meeting, Poster 1447, 1997.				
-0	PJ	Jovanovic, et al.,"IL-17 stimulates the secretion of proinflammatory cytokines by human			
macrophages," American College of Rheumatology (ACR)				, Poster 1446, November	
		1997.			
	PK-Lotz-et-al.,-IL-17-promotes-cartilage-degradation," Arthritis-and-Rheumatism, 39-				
		supp.(9):S120, No. 559, 1996.		a comment	
	PL	Spriggs, M. K., "Interleukin-17 and its receptor," J. Clin. Immunol., 17(5):366-369, 1997.			
D}		Spriggs, Mr. 12., Intercontain 17 and 18		V 100 ± 0	
	DM	Yao et al., "Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel			
	cytokine receptor," <i>Immunity</i> 3:811-821, 1995.  PN Yao et al., "Complete nucleotide sequence of the mouse <i>CTLA8</i> gene," <i>Gene</i> , 168:223-				
		1996.			
	   DO	Was at al. "Hymnon II. 17: A noval outs	king derived from T calls "	I Immunol 155:5483	
	PO Yao et al., "Human IL-17: A novel cytokine derived from T cells," J. Immunol., 155 5486, 1995.			J. Inmanon, 155.5465-	
				RECEIVED  MAR 2 2 2002  TECH CENTER 1600/2900	
				CEIVED	
				YF 3 5005	
		•	OF PAPERS	MAR 2 2 2 200/2900	
		ORIGI	NALLY FILED	CATER 1600 ED	
		Manager of the Control of the Contro		TECH CENTE	
				120	
	+				
EXAMINER DATE CONSIDERED					
Dona frana 5/6/02					
*EYAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if					
not in conformance and not considered. Include copy of this form with next communication to applicant.					

الرابات والمدواني يستعيب يبتدأ